LEO Pharma licenses new antihistamine from JW

24 August 2018

LEO Pharma, the privately-held Danish dermatology specialist, announced on Friday that it had reached an agreement with Korean pharma firm JW Pharmaceutical (KRX: 001060) to license JW1601, a dual-action antihistamine.

The deal will see LEO gain exclusive rights to develop, commercialize and market the drug worldwide, though JW will retain full rights in Korea. In return, JW will receive up to $385 million in milestone payments, as well as $17 million in fixed settlement payments. There will also be opportunities for JW to receieve royalty payments.

"We see a high unmet need for safe and effective oral treatments for people suffering from atopic dermatitis. It is therefore with great excitement that we partner with JW Pharmaceutical on its novel oral atopic dermatitis drug candidate, JW1601," said Kim Kjoeller, executive vice president for global R&D at at LEO.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK